Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Diamyd Medical

14.70 SEK

+4.11 %

Less than 1K followers

DMYD B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

+4.11 %
-6.01 %
+30.55 %
+45.83 %
+33.64 %
+74.98 %
+3.68 %
-51.36 %
+389.56 %

Diamyd Medical is active in diabetes research. The company has developed a vaccine that contains the active ingredient and molecule GAD, a substance that has the potential to be an important part of the prevention of diabetes treatments in the future. The company has operations on a global level with the largest presence in the Nordic region. The headquarters are located in Stockholm.

Read more
Market cap
2.03B SEK
Turnover
11.6M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
8.4.
2026

Extraordinary general meeting '26

24.6.
2026

Interim report Q3'26

7.10.
2026

Annual report '26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
Thanks to advanced AI tools (Google Gemini in this case), I was able to list the questions and answers from the Q&A section below. Note: watch the video yourself, AI can make mistakes, although I think the answers were correct) https://www.youtube.com/watch?v=qj2_tVpxIfY Summary ...
4 hours ago
by Junkbondking
14
Woah, what a bang! A quick Google search shows that the funds/investors involved now have such a track record that… woah, I need to let that sink in. And apparently this too: “The Company also announces completion of randomization in the pivotal precision medicine Phase 3 DIAGNODE...
3/23/2026, 8:59 AM
by Junkbondking
11
With a quick Google search, now there are funds/investors with such a track record that… wow, I need to process this. Wow… the more I investigate, the more it seems like a really big deal. I’m not familiar with these names myself, but every news article or AI-generated description...
yesterday
8
This GMP thing is a bit - well - important, but somewhat impossible for an investor to assess. But it’s something to consider, I have personal experience with it. I’m holding a couple of companies that have stumbled with GMP issues, Xspray and Telix. I believe the risk of regulators...
23 hours ago
by Clark kent
7
mb.cision.com 4002830.pdf 986.83 KB The Q2 report was exactly the non-event one would hope for at this stage. Ulf’s live comments can be found here starting at 10:00: https://www.youtube.com/live/qj2_tVpxIfY The factory updates in the report were naturally a welcome development, ...
yesterday
by Junkbondking
7
In addition to those you listed, an interesting point is Perceptive Advisors, which was involved in - drumroll - a certain Provention Bio. That’s the same company that had that drug Tzield with unpleasant side effects and about the same efficacy… It was sold to Sanofi for three billion...
yesterday
by Junkbondking
5
A retail investor shouldn’t be envious if their own portfolio is trading at those levels. This operation feels like it’s straight out of the big leagues, and there’s a buzz that suggests it’s worth holding on to.
3/23/2026, 7:53 AM
by Jummijammi2
4
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.